FastForward Innovations has officially rebranded as SEED Innovations Limited, a move approved by shareholders which reflects increasing investor appetite for the cannabinoid wellness and medical cannabis arenas.
As the only AIM quoted investor with direct exposure to pharmaceutical and medical cannabis, SEED will continue to demonstrate its expertise in the sector, notably following two of its portfolio assets selling for a combined value of over USD1 billion.
SEED are focused on investing in a balance of early-stage opportunities that have an upcoming investment catalyst, and more mature investments that offer liquidity in the near term. With many high growth start-ups staying private longer, access to such companies has been out of reach of the private investor; SEED is uniquely positioned to eliminate these barriers and provide access to potential high return opportunities. SEED’s goal is to level the playing field for the investor and see investment opportunities reserved for the ultra high net worth in the hands of small, medium, and large private investors alike.
Ed McDermott, CEO of FastForward, says: “We have seen significant investor interest in the cannabinoid sector and have participated in a number of new issues of late. We anticipate this trend to continue and believe we are perfectly positioned as the leading investor in the space.”
